Stock Scorecard



Stock Summary for Jazz Pharmaceuticals plc (JAZZ) - $207.83 as of 10/30/2026 6:23:01 PM EST

Total Score

7 out of 30

Safety Score

51 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for JAZZ

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for JAZZ

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for JAZZ

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for JAZZ

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for JAZZ (51 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 9
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 5
Trading Volume (Max of 10) 8
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for JAZZ

3 Healthcare Stocks To Own In October 2026 10/29/2026 8:10:00 AM
Jazz Pharmaceuticals (JAZZ) Following Fresh Ziihera Survival Data Looks Undervalued 10/28/2026 5:40:00 AM
Jazz Pharmaceuticals (JAZZ) Following Fresh Ziihera Survival Data Looks Undervalued 10/28/2026 5:11:00 AM
Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth Engine 10/27/2026 8:41:00 PM
JAZZ Q3'26 Earnings: revenue estimate is 1.21B USD 10/26/2026 11:41:00 PM
Jazz Pharmaceuticals slips 3.9% as investors appear to reposition ahead of earnings 10/26/2026 9:21:00 PM
Did Longer Survival Data Just Shift Jazz Pharmaceuticals' (JAZZ) Investment Narrative? 10/26/2026 1:40:00 AM
What Jazz Pharmaceuticals Doubters Missed 10/24/2026 6:40:00 AM
New Survival Data in HER2-Positive Gastroesophageal Adenocarcinoma at ESMO 2026 - Jazz Pharmaceuticals 10/23/2026 7:41:00 PM
Jazz Pharmaceuticals' Ziihera shows 3-year survival data in GEA 10/23/2026 2:41:00 PM

Financial Details for JAZZ

Company Overview

Ticker JAZZ
Company Name Jazz Pharmaceuticals plc
Country N/A
Description Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Dublin, Ireland.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 6/30/2026
Next Earnings Date 11/2/2026

Stock Price History

Last Day Price 207.83
Price 4 Years Ago 159.31
Last Day Price Updated 10/30/2026 6:23:01 PM EST
Last Day Volume 773,588
Average Daily Volume 833,702
52-Week High 266.38
52-Week Low 128.80
Last Price to 52 Week Low 61.36%

Valuation Measures

Trailing PE N/A
Industry PE 25.70
Sector PE 35.68
5-Year Average PE 13.87
Free Cash Flow Ratio 8.33
Industry Free Cash Flow Ratio 33.94
Sector Free Cash Flow Ratio 38.34
Current Ratio Most Recent Quarter 1.78
Total Cash Per Share 24.95
Book Value Per Share Most Recent Quarter 74.10
Price to Book Ratio 3.25
Industry Price to Book Ratio 7.66
Sector Price to Book Ratio 32.96
Price to Sales Ratio Twelve Trailing Months 3.02
Industry Price to Sales Ratio Twelve Trailing Months 29.18
Sector Price to Sales Ratio Twelve Trailing Months 24.60
Analyst Buy Ratings 13
Analyst Strong Buy Ratings 7

Share Statistics

Total Shares Outstanding 64,915,000
Market Capitalization 13,491,284,450
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 2.75%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 3.20%
Annual Earnings Growth -163.58%
Reported EPS 12 Trailing Months 14.59
Reported EPS Past Year 11.23
Reported EPS Prior Year 7.06
Net Income Twelve Trailing Months 940,763,000
Net Income Past Year -356,148,000
Net Income Prior Year 560,120,000
Quarterly Revenue Growth YOY 15.50%
5-Year Revenue Growth 12.54%
Operating Margin Twelve Trailing Months 26.90%

Balance Sheet

Total Cash Most Recent Quarter 1,619,800,000
Total Cash Past Year 1,391,899,000
Total Cash Prior Year 2,412,864,000
Net Cash Position Most Recent Quarter -1,715,200,000
Net Cash Position Past Year -2,936,455,000
Long Term Debt Past Year 4,328,354,000
Long Term Debt Prior Year 6,077,640,000
Total Debt Most Recent Quarter 3,335,000,000
Equity to Debt Ratio Past Year 0.50
Equity to Debt Ratio Most Recent Quarter 0.59
Total Stockholder Equity Past Year 4,318,584,000
Total Stockholder Equity Prior Year 4,093,756,000
Total Stockholder Equity Most Recent Quarter 4,801,700,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 1,542,330,000
Free Cash Flow Per Share Twelve Trailing Months 23.76
Free Cash Flow Past Year 1,146,021,000
Free Cash Flow Prior Year 1,347,838,000

Options

Put/Call Ratio 0.27
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 0.00
20-Day Bollinger Middle Band 0.00
20-Day Bollinger Upper Band 0.00
Beta 0.37
RSI 0.00
50-Day SMA 0.00
150-Day SMA 146.65
200-Day SMA 144.40

System

Modified 10/30/2026 2:43:30 AM EST